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In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best
regimen is not defined. We designed FOLFIRI-3 and conducted a phase II study to establish its efficacy and safety in advanced
colorectal cancer patients previously treated with FOLFOX. FOLFIRI-3 consisted of irinotecan 100mgm
 2 as a 60-min infusion on
day 1, running concurrently with leucovorin 200mgm
 2 as a 2-h infusion on day 1, followed by 46-h continuous infusion of
5-fluorouracil (5FU) 2000mgm
 2, and irinotecan 100mgm
 2 repeated on day 3, at the end of the 5FU infusion, every 2 weeks.
Sixty-five patients entered the study. The intent-to-treat objective response rate was 23% (95% CI 13–33%). Disease was stable in
37% of patients, progressed in 26% and was not assessable in 14%. From the start of FOLFIRI-3, median progression-free survival was
4.7 months and median survival 10.5 months. Main toxicities (% of patients) were grade 3–4 diarrhoea 23% and grade 4 neutropenia
11%. FOLFIRI-3 is a promising regimen achieving high response rate and progression-free survival in patients previously treated with
FOLFOX with a moderate toxicity.
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Colorectal cancer is the one of the commonest cancers worldwide
and remains a leading cause of mortality. For many years the main
treatment for metastatic colorectal cancer consisted of 5-fluoro-
uracil (5FU) modulated by leucovorin (LV). Since 1990, tremen-
dous progresses have been made through the availability of several
new drugs, such as oxaliplatin and irinotecan (Cunningham et al,
1998; Rougier et al, 1998; De Gramont et al, 2000; Douillard et al,
2000; Saltz et al, 2000; Grothey et al, 2002; Goldberg et al, 2004).
Irinotecan has definite activity against advanced metastatic
colorectal cancer both in chemotherapy-naive patients and after
5FU failure (Cunningham et al, 1998; Rougier et al, 1998; Douillard
et al, 2000; Saltz et al, 2000). Two randomised studies in patients
with 5FU bolus-resistant metastatic colorectal cancer established the
superiority of irinotecan over best supportive care (Cunningham
et al, 1998) or 5FU continuous-infusion regimens (Rougier et al,
1998). Later, two large multicentre randomised studies established
the superiority of irinotecan combined with 5FU and LV over
5FU–LV as first-line treatment of metastatic colorectal cancer
(Douillard et al, 2000; Saltz et al, 2000). Two additional
randomised studies demonstrated the superiority of oxaliplatin
combined with LV5FU2 (FOLFOX4) over 5FU and LV as front
therapy (De Gramont et al, 2000; Grothey et al, 2002). More
recently, in a large phase III study, FOLFOX4 achieved better
response rate, progression-free survival and overall survival than
the irinotecan-based IFL regimen as first-line treatment of
metastatic colorectal cancer (Goldberg et al, 2004). However, few
data are available about irinotecan-based chemotherapy in patients
previously treated with FOLFOX. Thus, the FOLFIRI regimen
achieved a 5% response rate in pretreated patients (Andre ´ et al,
1999; Tournigand et al, 2004).
In vitro studies suggested that the synergy between irinotecan
and 5FU is sequence dependent, with a higher cytotoxicity when
irinotecan is administered before 5FU (Guichard et al, 1997;
Mullany et al, 1998; Mans et al, 1999). Clinical data are less
documented. In a phase II randomised study evaluating the
sequence effect of irinotecan and 5FU, toxicities were affected by
the sequence of administration, with a worsened tolerability when
5FU was followed by irinotecan (Falcone et al, 2001). These results
suggested that cytotoxicity is higher when irinotecan is adminis-
tered after 5FU (Falcone et al, 2001). Thus, we previously designed
the FOLFIRI-2 regimen consisting of irinotecan 180mgm
 2
combined with a simplified LV5FU regimen, with irinotecan
administered at the end of the 5FU infusion (Mabro et al, 2003).
In this phase II study of patients with heavily pretreated colorectal
cancer, efficacy was encouraging, with a 17% confirmed response
rate and 4.1 months progression-free survival, but toxicity
was high.
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sThus, irinotecan-based chemotherapy after FOLFOX needs to be
improved and the best schedule is not yet established. We designed
a new regimen, FOLFIRI-3, in which irinotecan is administered as
two infusions: half-dose before 5FU and half-dose at the end of the
5FU infusion, and conducted this multicentre phase II study to
evaluate the efficacy of the FOLFIRI-3 regimen in advanced
colorectal cancer patients previously treated with FOLFOX regimen.
PATIENTS AND METHODS
This study was an open multicentre phase II study conducted from
June 2001 to December 2002. The study fulfilled the Clinical Good
Practice Guidelines and was approved by the Ethics Committee of
La Pitie ´ – Salpe ˆtrie `re Hospital, Paris, France. Written informed
consent was obtained from all patients prior to study entry.
The main end point of the study was progression-free survival.
The other study parameters were: response rate, overall survival
and toxicity.
Inclusion criteria
Patients were required to be 18–80 years old, and to have
metastatic adenocarcinoma of the colon or the rectum histologi-
cally proven and previously treated with a FOLFOX regimen. An
interval of at least 2 weeks must have elapsed since prior
treatment. Other eligibility criteria were: no central nervous
system metastases, WHO performance status 0–2, initial evalua-
tion p2 weeks before inclusion by computed tomography scan
prior to initiation of therapy and feasibility of regular follow-up.
Required laboratory parameters included: neutrophil count
X1500ml
 1, platelet count X100000ml
 1, serum alkaline phos-
phatase o3 times the upper limit of normal (ULN) and bilirubin
o1.5 times ULN.
Treatment administration
FOLFIRI-3 regimen was given every 14 days as follows: on day 1,
irinotecan 100mgm
 2 as a 1-h infusion, running concurrently
with LV 200mgm
 2 as a 2-h infusion via a Y-connector, followed
by 5FU 2000mgm
 2 as a 46-h infusion using a disposable
elastomeric pump. On day 3, irinotecan 100mgm
 2 as a 1-h
infusion was repeated, at the end of the 5FU infusion (Figure 1). In
the absence of grade 2 toxicity after two cycles, the dose of
irinotecan was to be increased from 100 to 120mgm
 2 at days 1
and 3. Treatment was continued until disease progression or
limiting toxicity.
Leucovorin 200 mg m–2  
120 min 
5FU bolus 
400 mg m–2
Irinotecan 
180 mg m–2
90 min 
5-fluorouracil 46-h continuous infusion 
2400 mg m–2 
FOLFIRI: Irinotecan day 1 followed by bolus 5FU and 46-h continuous 5FU. 
Leucovorin 200 mg m–2  
Leucovorin 200 mg m–2  
120 min 
5-fluorouracil 46-h continuous infusion 
2400 mg m–2  
Irinotecan 
180 mg m–2  
90 min 
FOLFIRI-2: Irinotecan on day 3 at the end of 5FU infusion, plus hydroxyurea given the day 
before, day 1 and day 2 of each cycle. 
120 min 
Irinotecan 
100 mg m–2  
60 min 
5-fluorouracil 46-h continuous infusion 
2000 mg m–2  
Irinotecan 
100 mg m–2  
60 min 
FOLFIRI-3: Double infusion of irinotecan before (day 1) and at the end of 5FU infusion (day 3). 
Figure 1 Design of FOLFIRI (Andre ´ et al, 1999), FOLFIRI-2 (Mabro et al, 2003) and FOLFIRI-3 regimens; cycles are repeated every 2 weeks.
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sBlood tests and clinical evaluation were performed every 2
weeks, prior to treatment. Chemotherapy could be administered if
neutrophil count was X1500ml
 1, platelet count X100000ml
 1
and if clinical toxicity was resolved or ograde 2. In case of grade
42 neutropenia, thrombocytopenia or diarrhoea toxicity, the dose
of irinotecan was to be reduced from 100 to 80mgm
 2.I f
neutropenia, thrombocytopenia or diarrhoea 4grade 2 persisted
at this latter dose, chemotherapy was discontinued.
Supportive care
Specific anti-emetic prophylaxis was left to the investigator’s
discretion. For patients who experienced an early cholinergic
syndrome occurring during or shortly after irinotecan adminis-
tration, atropine sulphate (0.25mg) could be given subcuta-
neously. The use of loperamide was recommended in case of
diarrhoea.
Study parameters
Before each cycle, patients underwent a clinical examination, and
blood cells were counted. All toxicities were reported according to
the National Cancer Institute-Common Toxicity Criteria (NCI-
CTC) (MacDonald et al, 1995). Carcinoembryogenic antigen,
bilirubin, serum alkaline phosphatases, serum creatinine, lactate
dehydrogenase, chest X-ray and CT scans were repeated every 8
weeks (i.e. every four cycles) or earlier in the case of worsening of
clinical condition. Tumour response was assessed by RECIST
criteria (Therasse et al, 2000). Tumour growth control was defined
by the proportion of patients with response rate or stable disease.
Statistical considerations
Based on previous studies, we expected FOLFIRI-3 to achieve a
40% rate of nonprogressive patients at 6 months. According to a
binomial distribution point estimate of proportion, with 5%
significance and 80% power, 65 patients were to be enrolled.
Survival times were calculated from the start of FOLFIRI-3 until
death. Time to progression was calculated from the first day of
FOLFIRI-3 to the date of progression for all the patients entering
the study. Survival curves were obtained using the Kaplan–Meier
method (Kaplan and Meier, 1958).
RESULTS
From 17 June 2001 to 19 December 2002, 65 patients were recruited
from nine French institutions. Their characteristics are described
in Table 1. All patients had previously been treated with a FOLFOX
regimen (combination of oxaliplatin, infusion 5FU and LV), and
had experienced disease progression while on FOLFOX (36
patients) or after discontinuation (29 patients). Thirteen patients
(20%) had previously been treated with at least two regimens for
metastatic purpose before entering the FOLFIRI-3 study.
Treatment
The median number of treatment cycles administered was 7
(range, 1–20). Six patients (9%) refused to continue after the first
or the second course (personal convenience without toxicity
4grade 2). In six patients (9%) treatment was stopped because of
grade 3 or 4 toxicity. Tumour response was not assessable in nine
of those 12 patients. In 39 patients (60%) treatment was stopped
because of disease progression after a median of eight courses. In
14 additional patients (21%) chemotherapy was interrupted by
investigator after 8–20 cycles, without evidence of disease
progression nor severe toxicity.
Dose reductions occurred in 25 patients due to grade 3
toxicities, mainly vomiting, diarrhoea or mucositis. Irinotecan
dose was increased according to the design of the study only in 12
patients with a median dose level of 120mgm
 2 on days 1 and 3.
Grade 3 toxicity occurred only in one of these patients.
Safety
Side effects were collected for 463 cycles according to the NCI-CTC
grade scale. Toxicities are listed in Table 2. Neutropenia reached
grade 3/4 in 37% of patients, including three patients (5%) who
had one episode of febrile neutropenia. There was one toxic death
after the first course of chemotherapy related to a sepsis shock
with neutropenia and diarrhoea. Overall, 10 patients (15%)
experienced at least one grade 4 toxicity and 20 patients (31%)
experienced one grade 3 nonhematological toxicity.
Survival and objective response
Progression free survival for 6 months was 42%. From the start of
FOLFIRI-3, median progression-free survival was 20.5 weeks (4.7
months) and median survival was 46 weeks (10.5 months). Survival
curves are shown in Figure 2.
Tumour response was assessable in 56 patients and not
assessable in nine patients (14%). Response rates were calculated
in the intent-to-treat population. Objective response was obtained
in 15 patients (1 complete, 14 partial), achieving a 23% (95% CI
13–33%) response rate (15 out of 65). The number of responder
Table 1 Patient characteristics (n¼65)
N %
Median age: 60 years (range: 30–79)
Gender
Male 32 49
Female 33 51
WHO performance status
03 2 4 9
12 2 3 4
21 1 1 7
Primary tumour
Colon 49 75
Rectum 16 25
Site of metastases
Liver 52 80
Lung 23 35
Peritoneum 9 14
Nodes 11 17
Other 6 9
Involved sites
13 6 5 5
22 3 3 5
426 9
Prior adjuvant chemotherapy: 13 20
LV5FU 11 17
FOLFOX 2 3
Number of lines for metastatic purpose received before FOLFIRI-3
1 line only 52 80
2 lines or more 13 20
FOLFOX regimen received before FOLFIRI-3
FOLFOX7 27 42
FOLFOX6 13 20
FOLFOX4 25 38
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spatients assessed by RECIST criteria are listed in Table 3. Disease
was stable in 24 patients (37%) and progressed in 17 (26%).
Tumour growth control was 60% (95% CI 48–72%).
Regarding assessable patients, response rate was 27% (95% CI
15–39%), and 22% in the subset of patients in whom disease
progressed while on previous FOLFOX regimen, and 33% in the
subset of patients in whom disease progressed after FOLFOX
discontinuation.
DISCUSSION
This multicentre phase II study assessed the efficacy and
tolerability of the FOLFIRI-3 regimen, a new combination of
irinotecan and LV5FU, in patients with metastatic colorectal
cancer previously treated with FOLFOX. With 42% of patients free
of progression at 6 months, the main objective of the study was
reached.
Several phase II studies (Pitot et al, 1997; Rougier et al, 1997;
Rothenberg et al, 1999; Van Cutsem et al, 1999) and two large
phase III studies (Cunningham et al, 1998; Rougier et al, 1998)
established the efficacy of irinotecan after 5FU failure (Table 4). In
phase II studies of irinotecan alone, after 5FU failure response
rates were 11–16% (Rougier et al, 1997; Rothenberg et al, 1999;
Van Cutsem et al, 1999), and progression-free survival was 3–4
months (Pitot et al, 1997; Rougier et al, 1997; Rothenberg et al,
1999; Van Cutsem et al, 1999). In phase III studies of irinotecan
after 5FU failure, progression-free survival was 3–4 months
(Cunningham et al, 1998; Rougier et al, 1998; Fuchs et al, 2003).
Response rate was reported in only one of those studies and was
4.5% (Rougier et al, 1998).
The combination of irinotecan with 5FU and LV after 5FU
failure was evaluated in three phase II studies. Reported response
rates were 11.4–21% (Ducreux et al, 1999; Gil-Delgado et al, 2001;
Rougier et al, 2002). As shown in Table 4, results observed with
regimens combining irinotecan, 5FU and LV after 5FU failure seem
slightly better than those with irinotecan alone, in a cross-study
comparison. More recently, a large randomised phase III study was
conducted enrolling more than 2000 patients. In this study, the
addition of irinotecan to 5FU after 5FU failure achieved better
survival (14.8 vs 13.9 months from the start of front-line 5FU) and
higher response rate (21 vs 11%) than irinotecan alone after 5FU
failure (Seymour et al, 2005). These results encourage the
administration of 5FU with irinotecan despite previous 5FU
failure.
Efficacy of irinotecan in patients previously treated with
FOLFOX is less documented. Results of the FOLFIRI, FOLFIRI-2
and FOLFIRI-3 studies are summarised in Table 4. In a
randomised trial recently reported, irinotecan alone achieved a
4% response rate and 2.7 progression-free survival in 94 patients
previously treated with 5FU as front line and FOLFOX4 as second
line (Rowland et al, 2005).
In the present study, the progression-free survival was 4.7
months and the intent-to-treat response rate was 23%, higher than
those reported with irinotecan alone, FOLFIRI and FOLFIRI-2 after
FOLFOX. In a cross-study comparison, efficacy of FOLFIRI-3
seems slightly better than FOLFIRI-2, as FOLFIRI-2 showed a high
toxicity profile. The main FOLFIRI-2 grade 3–4 toxicities were
diarrhoea (31%), neutropenia (52%), and febrile neutropenia
(14%) (Mabro et al, 2003). Toxicity of FOLFIRI-3 was moderate,
lower than FOLFIRI-2 study and quite higher than FOLFIRI in
pretreated patients (Andre ´ et al, 1999). It is difficult to assess if this
increased toxicity is related to the divided dose of irinotecan or to
the total dose of irinotecan, which is 10% more than in the
FOLFIRI (200 instead of 180mgm
 2 per cycle). Differences should
be also partly due to the subset of patients. In particular, patients
Table 2 Toxicity of FOLFIRI-3 according to NCI-CTC grading (maximal
grade per patient, collected from 463 cycles, 65 patients)
NCI-CTC grade (% of patients)
1234
Nonhaematological toxicities
Nausea 28 29 9 0
Vomiting 12 19 8 0
Mucositis 20 19 5 2
Diarrhoea 25 38 22 1
Asthenia 28 20 11 3
Hand–foot syndrome 23 2 0 —
Alopecia 23 54 — —
Haematological toxicities
Neutropenia 14 28 26 11
Febrile neutropenia — — 2 3
Anaemia 54 26 2 2
Thrombocytopenia 34 5 3 0
NCI-CTC, National Cancer Institute-Common Toxicity Criteria.
0 2 4 6 8 10 12 14 16 18 20 22 24
0.00
0.25
0.50
0.75
1.00
PFS
OS
Time (month)
P
r
o
p
o
r
t
i
o
n
Figure 2 Progression-free survival and overall survival in the FOLFIRI-3
study (65 patients).
Table 3 RECIST number of the responder patients
Patient no. Response
RECIST at
baseline
RECIST at
first
evaluation
RECIST at
second
evaluation
103 PR 38 18 20
105 PR 10 6 3
108 PR 275 230 175
112 PR 114 45 50
113 PR 102 81 25
202 PR 90 90 65
212 PR 78 48 55
205 PR 20 10 10
301 PR 74 48 91
306 PR 80 70 44
308 PR 180 160 118
501 PR 100 90 70
505 PR 50 21 19
803 PR 131 90 78
404 CR 85 35 0
RECIST, Response Evaluation Criteria in Solid Tumors.
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sof the FOLFIRI-3 study were less selected and 17% entered the
study with a PS 2.
In conclusion, FOLFIRI-3 is a feasible regimen with encour-
aging response rate and progression-free survival in patients
previously treated with FOLFOX. Future studies should
evaluate the combination of FOLFIRI-3 with molecular targeted
therapies like bevacizumab, cetuximab or new oral anti-REGF
molecules.
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